One Day In July LLC Buys 401 Shares of Johnson & Johnson $JNJ

One Day In July LLC grew its holdings in Johnson & Johnson (NYSE:JNJ) by 16.9% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 2,773 shares of the company’s stock after purchasing an additional 401 shares during the quarter. One Day In July LLC’s holdings in Johnson & Johnson were worth $424,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently bought and sold shares of the company. GFG Capital LLC acquired a new position in Johnson & Johnson in the second quarter worth $35,000. Stone House Investment Management LLC acquired a new position in Johnson & Johnson in the first quarter worth $47,000. 1248 Management LLC acquired a new position in Johnson & Johnson in the first quarter worth $48,000. von Borstel & Associates Inc. acquired a new position in shares of Johnson & Johnson during the first quarter valued at $49,000. Finally, Harvest Fund Management Co. Ltd acquired a new position in shares of Johnson & Johnson during the first quarter valued at $52,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Trading Down 0.3%

NYSE:JNJ opened at $186.39 on Thursday. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $194.48. The business’s 50-day moving average price is $182.88 and its two-hundred day moving average price is $167.17. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50. The firm has a market capitalization of $449.07 billion, a price-to-earnings ratio of 17.99, a PEG ratio of 2.20 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The company had revenue of $24.02 billion during the quarter. On average, equities analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be issued a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 2.8%. The ex-dividend date is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio is 50.19%.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on JNJ. Piper Sandler reaffirmed an “overweight” rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. Wall Street Zen raised Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Saturday, September 13th. Morgan Stanley set a $190.00 price target on Johnson & Johnson in a research note on Wednesday, October 15th. Guggenheim raised Johnson & Johnson from a “neutral” rating to a “buy” rating and upped their price target for the company from $167.00 to $206.00 in a research note on Tuesday, September 23rd. Finally, Wells Fargo & Company set a $212.00 target price on Johnson & Johnson and gave the company an “overweight” rating in a research note on Friday, October 3rd. Three research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $199.05.

Insider Activity

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the sale, the executive vice president directly owned 178,013 shares in the company, valued at $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.